Mount Vernon Hospital
Welcome,         Profile    Billing    Logout  
 24 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hoskin, Peter J
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
Ardeshna, Kirit
CRUK-2004-001621-16, NCT00112931 / 2004-001621-16: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Checkmark P3 data
Jun 2011 - Jun 2011: P3 data
Checkmark P3 data
Dec 2010 - Dec 2010: P3 data
Completed
3
462
Europe, RoW
rituximab, No treatment
University College, London, Cancer Research UK, Roche Pharma AG
Lymphoma
03/14
09/23
Nathan, Paul
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
Lambert, Jonathan
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
Grønberg, Bjørn H
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
ASTEROID, NCT03446547: Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

Recruiting
2
106
Europe
Durvalumab, Medi4736
Vastra Gotaland Region, AstraZeneca
NSCLC, Stage I
07/24
07/24
DART, NCT04392505 / 2019-002537-11: Durvalumab(MEDI4736) After chemoRadioTherapy() for NSCLC-a Translational and Biomarker Study

Active, not recruiting
2
100
Europe
Durvalumab Injection, Imfinzi
Oslo University Hospital, AstraZeneca
Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC, NSCLC, Stage III
05/25
05/33
Walshe, Janice
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Harrison, Mark
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
Polychronis, Andreas
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
300
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, Belrestotug, EOS884448, GSK4428859A, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
01/25
01/28
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Serwatowski, Piotr
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
01/25
10/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Checkmark Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
Sutherland, Stephanie
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
Ananthi, Balasubramanian
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Aamelfot, Christina
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29

Download Options